Marinomed Biotech sells stake in company

6 October 2015
mergers-acquisitions-big

Austrian biotech firm Marinomed Biotechnologie on Tuesday said it has sold a stake in the company to the investment fund aws Mittelstandsfonds for an undisclosed sum in a bid to boost its expansion plans.

The company said the funds from the deal will provide “significant financial means” and help accelerate the global roll-out of its cold and influenza products.

Andreas Grassauer, chief executive of Marinomed, said: "Nasal sprays developed by Marinomed have been approved in 48 countries and these OTC products are well in demand. Our forthcoming investment will accelerate this global market entry. Simultaneously we will continue our focused development of innovative products and thus fill our pipeline even further."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology